Cardio Diagnostics Holdings is set to showcase its AI-driven cardiovascular risk assessment tools at several national benefits conferences this June, targeting key stakeholders in healthcare management.
The company plans to present its innovative solutions, including Epi+Gen CHD(TM), PrecisionCHD(TM), and the HeartRisk(TM) platform. These tools aim to identify individuals at risk for cardiovascular diseases earlier, which could aid employers, brokers, and plan administrators in managing healthcare costs more effectively. With cardiovascular disease being a leading cause of death and a major contributor to healthcare expenses, Cardio Diagnostics seeks to transition from reactive treatments to proactive prevention through its advanced AI technology.
By engaging with stakeholders at these conferences, Cardio Diagnostics is positioning itself as a critical player in the healthcare landscape, focusing on data-driven strategies to mitigate risks associated with cardiovascular events. The company’s proprietary Core Technology underpins its clinical tests, enhancing the precision and accessibility of cardiovascular disease management.
This initiative highlights the growing recognition among employers and union trustees of the need to balance healthcare costs with improved employee health outcomes. As Cardio Diagnostics continues to develop its offerings, it aims to lead the way in transforming cardiovascular medicine through innovative technology.